Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
GNB2L1
REST API REST API
Homo sapiens
GNB2L1 is differentially expressed in 305 experiments: 163 organism parts: liver, amygdala, ... (161 more);, 231 disease states: normal, acute myeloid leukemia, ... (229 more);, 99 cell types 407 cell lines 36 compound treatments and 78 other conditions.
Synonyms RACK1, Gnb2-rs1, H12.3
Orthologs Gnb2l1 (Mus musculus)   ASC1 (Saccharomyces cerevisiae)   GBLP_CHICK (Gallus gallus)   GBLP_BOVIN (Bos taurus)   ENSCING00000015569 (Ciona intestinalis)   ENSCING00000004025 (Ciona intestinalis)   gnb2l1 (Danio rerio)   Gnb2l1 (Rattus norvegicus)   Rack1 (Drosophila melanogaster)   gnb2l1 (Xenopus laevis)   GNB2L1 (Canis familiaris)   (Compare orthologs)
InterPro Term WD40_repeat_dom, WD40_repeat, WD40_repeat_2, G-protein_beta_WD-40_rep, WD40_repeat_subgr
Gene Ontology Term plasma membrane, negative regulation of cell growth, protein binding, SH2 domain binding, cytoskeleton, cytoplasm, positive regulation of proteasomal ubiquitin-dependent protein catabolic process, small ribosomal subunit, receptor binding, regulation of protein localization, positive regulation of apoptosis, negative regulation of Wnt receptor signaling pathway, midbody, multicellular organismal development, rhythmic process, regulation of cell cycle, nucleus, cell projection, dendrite, regulation of cell division, perinuclear region of cytoplasm, negative regulation of translation, positive regulation of GTPase activity, regulation of growth, neuronal cell body, perikaryon, receptor tyrosine kinase binding, positive regulation of cell migration, protein kinase C binding, interspecies interaction between organisms, ion channel inhibitor activity, protein tyrosine kinase inhibitor activity, protein phosphatase binding, negative regulation of protein tyrosine kinase activity, negative regulation of phagocytosis, phagocytic cup, positive regulation of protein phosphorylation, positive regulation of gastrulation, positive regulation of protein homooligomerization, regulation of establishment of cell polarity
UniProt Accession D6R9L0, D6R909, D6R9Z1, D6RAC2, D6REE5, D6RF23, D6RDF4, D6RDI0, D6RAU2, D6RBD0, D6RHH4, D6RHJ5, D6RGK8, D6RFX4, D6RFZ9, P63244, E9PD14, E9KL35
Search EB-eye ENSG00000204628
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (38 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
HepG2
2
E-GEOD-21154, E-MTAB-37
T84
2
E-GEOD-1474, E-MTAB-37
MDA468
2
E-MEXP-440, E-MTAB-62
SW480
2
E-MEXP-1014, E-MTAB-37
primary culture
2
E-GEOD-2450, E-GEOD-1657
401 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, ... (40 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-AFMX-5, E-TABM-145
CD34+Thy+ hematopoietic stem cell
1
E-GEOD-96
CXCR4 negative
1
E-GEOD-15893
hematopoietic stem cell
1
E-MEXP-1403
CD34+ cell
1
E-MEXP-583
embryonic stem cell
1
E-MEXP-930
93 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (67 experiments)

Factor Value U/D Experiments
control
1
3
E-GEOD-21912, E-GEOD-16363, E-GEOD-20168, E-GEOD-8121
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
lung carcinoma
2
E-GEOD-6014, E-MTAB-37
dermatomyositis
2
E-MTAB-62, E-GEOD-5370
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-96
225 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (24 experiments)

Factor Value U/D Experiments
none
3
7
E-GEOD-5824, E-TABM-782, E-MEXP-1601, E-GEOD-412, E-GEOD-2803, ... (10 experiments)
control
2
E-GEOD-3284, E-GEOD-995
lipopolysaccharide
1
2
E-TABM-868, E-MEXP-1958, E-GEOD-3720
vanadium pentoxide
1
E-GEOD-5339
mannitol
1
E-GEOD-6400
phoshate buffered saline
1
E-GEOD-3720
30 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-1563, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, E-TABM-440, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, E-GEOD-6434, E-GEOD-1657, ... (8 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-19743, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Tissue
studied in E-GEOD-30573

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541, E-TABM-147

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.316 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM